AIM ImmunoTech’s Proxy Contest

Kirkland & Ellis advised AIM ImmunoTech on the deal. AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here